关于“基因检测”的报告
艾媒咨询 | 2024年中国母婴市场发展状况与消费者调研报告
受三孩政策驱动，中国生育率有望得到提升，政策及相关配套措施落地将带动母婴消费新增量。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024年中国母婴市场发展状况与消费者调研报告》数据显示，中国母婴行业市场规模逐年稳步增长，2023年达66478亿元，预计2027年将达到89149亿元，呈现显著的上升趋势。
Driven by the three-child policy, China's fertility rate is expected to be increased, and the landing of policies and related supporting measures will drive new increases in maternal and infant market. According to the latest "China Maternal and Infant Market Development and Consumer Research Report in 2024" released by iiMedia Research, a third-party data mining and analysis institution in the global new economy industry, the market size of China's maternal and infant industry has grown steadily year by year, reaching 6,647.8 billion yuan in 2023. It is expected to reach 8914.9 billion yuan in 2027, showing a significant upward trend.-
艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告
美国将幽门螺杆菌被列为明确致癌物后，幽门螺杆菌在中国受到了极大的关注。iiMedia Research（艾媒咨询）数据显示，2021年中国幽门螺杆菌检测市场规模73.1亿元，预计2022年将达到86.6亿元。艾媒咨询分析师认为，随着大众的健康意识逐渐加强，幽门螺杆菌自测产品将成为必需品，幽门螺杆菌检测市场发展空间广阔。而幽门螺杆菌自测产品的上市，有助于推动居家检测。(《艾媒咨询｜2022年中国幽门螺旋杆菌检测市场专题调查报告》完整高清PDF版共23页，可点击文章底部报告下载按钮进行报告下载)
After the United States Department of Health & Human Services listed Helicobacter pylori as a definitive carcinogen, Helicobacter pylori received great attention in China. According to data from iiMedia Research, the market size of Helicobacter pylori testing in China will be 7.31 billion yuan in 2021 and is expected to reach 8.66 billion yuan in 2022. With increasing health awareness, Helicobacter pylori self-test product is necessary for people. The market for Helicobacter pylori self-test product is vast. The launch of Helicobacter pylori self-test products helps to promote home testing.（“iiMedia Report ｜Investigation Report on The Market of Helicobacter Pylori Testing in China in 2022”full version has 23 pages, please click the Browse HD Report button on the right side of the article to browse the report） -
-
艾媒咨询|2021年3-4月中国母婴行业月度运行数据监测报告
本报告研究涉及企业/品牌/案例：贝康医疗，锦欣生殖，美吉姆，红黄蓝
在人口老龄化加速发展的背景下，我国的生育政策保持利好。但是受到晚婚晚育及二孩大龄母亲等影响，辅助生育产业得到高速发展，2020年的市场规模达到354.73亿元。同时，婴儿早教行业在疫情后回复发展，iiMedia Research(艾媒咨询)数据显示，2021年，中国家长在挑选早教课程的考虑因素中，最重要的是早教内容的专业度和丰富度，占比分别高达64.1%和63.3%。
In the context of the accelerated development of population production, the birth policy has been maintained well. At the same time, early childhood education is affected by marriage and parenting and older mothers with two children, and the assisted reproductive industry has been developed. The market size in 2020 will reach 354.73. At the same time, the infant early education industry has resumed development after the epidemic was revealed. According to data from iiMedia Research, in 2021, among the factors that Chinese parents consider when choosing early education courses, the most important factor is the professionalism and degree of early education content, which will eventually be as high as 64.1% and 63.3%. -
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例：华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势，细胞生物临床研究不断深化，伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成，生态圈的完善将在很大限度上推动产业快速发展。数据显示，中国细胞治疗企业融资金额不断增加，从2014年的0.2亿元增长至2019年的28.9亿元。其中，2018年中国细胞治疗企业融资额同比增长706.8%，呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇，同时也有挑战并存。后续产业的发展，将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局，企业也应积极开展生态合作以及更为密切关注市场需求动向，将疗法和新一代医疗创新技术深度融合，实现市场产品多元化与差异化，并推出独特性的精准治疗，从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒报告|2020年中国医用防护物资产业运行、监管及机遇分析报告
2020年4月5日，全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020年中国医用防护物资产业运行、监管及机遇分析报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据，对2020年中国医用防护物资及其细分领域进行分析。特别针对2020年3月商务部等联合发布的《关于有序开展医疗物资出口的公告(2020年第5号)》新规定，对2020-2021年的中国医疗物资行业的发展趋势进行分析预判。截至北京时间2020年4月3日10时，全球共累计确诊1010702人。口罩、防护服等医疗防护用品已成为全球紧缺的必需品，但应注意疫情过去之后医疗防护用品可能面临产能过剩等问题，如何平衡行业产能是相关企业需要考虑的问题。
Medical protective equipment is a global necessity during the epidemic. This has become a new opportunity for Chinese companies and brands to go overseas. However, we must pay attention to the quality control of Chinese brands. In the future, branding and specialization will become the core competitiveness of domestic medical protective equipment manufacturers. . -
艾媒报告|2019年12月-2020年1月中国医疗器械行业运行及上市公司双月度报告
本报告研究涉及企业/品牌包括:Mavidon,Titan Medical,Aspire Capital Fund,CentriMag,汇桥资本集团,联影医疗技术集团,医达极星,大博医疗,安捷伦,润扬医疗器械,迈瑞医疗,乐普医疗,威高医用,华大基因,安图生物,健帆生物,鱼跃医疗,京东方科技,美亚光电,东软集团,祥生医疗,硕世生物,佰仁医疗,爱博诺德,伟思医疗,安必平,林华医疗,拱东医疗,天智航,三友医疗,赛科希德等。
截至 2020 年 1 月 31 日 24:00，国家卫生健康委员会公布全国确诊病例 11791 例，重症病例 1795 例。短期来看，预计疫情将继续持续一段时间。肺炎疫情期间，病毒检测带动试剂盒需求增加；病毒治疗带动医用设备及医用耗材需求增加。部分医疗器械企业有望构成业绩增厚。
As of 24:00 on January 31, 2020, the National Health Commission announced 11791 confirmed cases and 1795 severe cases. In the short term, the outbreak is expected to continue for some time. During the pneumonia epidemic, virus detection drives demand for kits; virus treatment drives demand for medical equipment and supplies. Some medical device companies are expected to increase their performance. -
艾媒报告 |2019中国短视频电商行业现状及发展前景分析报告
本报告研究涉及企业/品牌/案例：快手，如涵控股，三只松鼠，海底捞，铂爵旅拍，抖音，小红书，西瓜视频，微信，B站，百草味，良品铺子，东鹏特饮，旺仔俱乐部，大希地，美拍，火山小视频，巴黎欧莱雅，SK-II,搜狐视频，京东，淘宝,土豆视频，快视频，波波视频
目前中国短视频电商主要有三种运营模式，并开始出现综合类平台和垂直类平台两种类型。艾媒数据中心数据显示，短视频电商主要依靠KOL粉丝转化，最能推动服装、休闲零食、美妆等产品转化。艾媒咨询分析师认为，目前短视频电商仍面临供应链、内容生态等发展困境，未来将向受众多元化、内容多元化、主播多元化、形式多元化的方向发展。
At present, there are three main operating modes for short video e-commerce in China, and there are two types of integrated platforms and vertical platforms. Ai Media Data Center data shows that short video e-commerce mainly relies on KOL fans to transform, which can promote the transformation of clothing, casual snacks, beauty and other products. Ai Media Consulting analysts believe that the current short video e-commerce still faces the development dilemma of supply chain and content ecology. In the future, it will diversify its audience, diversify its content, diversify its anchors and diversify its forms. -
艾媒报告 |2019中国基因测序产业研究和商业应用分析报告
本报告研究涉及企业/品牌/案例：Thermo Fisher（美），Illuminate（美），（瑞士），Stem cells（加），R&D（瑞士），华大基因，贝瑞基因，金城检验，美吉生物，恒创基因，基研生物，谱元科技，景杰生物，燃石生物，基迪奥生物，谷和信息，圣庭生物，天昊生物，诺禾致源，百迈克生物，思博奥科，赛莱拉，赛贝、北昊干细胞，达安基因，燃石医学、泛生子基因、世和基因，臻和生物，鹍远基因，23魔方，瀚海基因，百奥赛图，克睿基因，药明明码，裕策生物
随着基因测序的技术推进，基因测序开始应用于生物、侦查、无创产前检测和肿瘤治疗等场景中。技术的市场化应用吸引了全球资本方关注，iiMedia Research（艾媒咨询）数据显示，2018年全球医疗健康领域资本市场中，生物技术领域获得309件投资案共138亿元美元，领跑所有细分领域。中国生物技术科研研发实力厚积薄发，特别是科创板推动了基因测序市场的进一步升温，越来越多的生物创业公司在创业初期已获得高额融资。目前，中国已经基本形成了完整的上中下游产业链，但除了华大基因、贝瑞基因等少数头部企业，中国基因测序企业多数分布于产业链中下游，并且开始出现产品同质化等问题。艾媒咨询分析师认为，第二代测序技术的普及以及第三代测序技术的加紧研发将使得基因测序作为一个更加普遍的技术手段应用到不同场景之中，但目前仍然存在监管体系不够完善、道德伦理风险等问题。企业方面应当专注研究核心技术专利，通过人才储备和差异化竞争获得市场优势；行业和相关部门应当尽快完善行业规范管理体系，推动产业健康发展。
With the advancement of gene sequencing technology, gene sequencing began to be used in biological, detection, noninvasive prenatal testing and tumor treatment and other scenarios. The market-oriented application of technology has attracted global capital attention, with iiMedia Research leading all segments of the world in 309 investments in the global healthcare capital markets in 2018, with 309 investments, according to iiMedia Research. China's biotechnology research and development strength thick and thin hair, especially the science and technology board to promote the gene sequencing market further heating up, more and more bio-startup companies in the early stage of the start-up has been high financing. At present, China has basically formed a complete upstream and downstream industrial chain, but in addition to Huada gene, Berry gene and a few other head enterprises, Most of China's gene sequencing enterprises are distributed in the middle and lower reaches of the industrial chain, and began to appear product homogenization and other issues. Ai media consulting analysts believe that the popularity of second-generation sequencing technology and the third generation of sequencing technology will make gene sequencing as a more common technical means to apply to different scenarios, but there are still problems such as inadequate regulatory system, ethical risks. Enterprises should focus on researching core technology patents and gain market advantages through talent pool and differentiated competition, and industries and related departments should improve the industry standard management system as soon as possible to promote the healthy development of the industry. -
- 1
- 2
